Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R)

Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R)

Novel therapeutic approaches are much needed for the treatment of osteosarcoma. Targeted radionuclide therapy (TRT) and radioimmunotherapy (RIT) are promising approaches that deliver therapeutic radiation precisely to the tumor site. We have previously developed a fully human antibody, named IF3, th...

Full description

Bibliographic Details
Main Authors: Chandra B. Prabaharan, Sabeena Giri, Kevin J. H. Allen, Katrina E. M. Bato, Therese R. Mercado, Mackenzie E. Malo, Jorge L. C. Carvalho, Ekaterina Dadachova, Maruti Uppalapati
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Molecules
Subjects:
osteosarcoma (OS)
insulin-like growth factor 2 receptor (IGF2R)
monoclonal antibodies
neonatal Fc receptor (FcRn)
radioimmunotherapy (RIT)
Online Access:https://www.mdpi.com/1420-3049/28/15/5839

Internet

https://www.mdpi.com/1420-3049/28/15/5839

Similar Items